Results 1 - 20 of 870 in Amgen
-
Health Winners & Losers: Abbott Labs
... in fact, was in the green, with the exception of King Pharmaceuticals KG . King gave up 22 cents, or 2%, to $10.49. Amgen AMGN , AstraZeneca AZN , GlaxoSmithKline GSK and Sanofi-Aventis SNY were each with 3%-plus gains. Meanwhile, Abbott ...
Comment?
-
... he said. The study, published in the July 3 issue of the New England Journal of Medicine , was funded by drug maker Amgen Inc. Motesanib diphosphate - a VEGF inhibitor - targets a protein called vascular endothelial growth factor (VEGF), which plays ...
Comment?
-
Biotech-Stock Mailbag: Amgen, MiddleBrook
... Profits"). The Biotech Mailbag is open, even on the Fourth of July. The first email is from F. Mace, who asks: "Why is Amgen AMGN selling at such a discount to Celgene CELG and Genentech DNA ? Do you think in the next six months biotechs as a group ...
Comment?
-
Nasdaq 100 Leaders and Laggards: Amgn Nvda
... Department said the nation's unemployment rate held steady at 5.5 percent last month. Shares of biotechnology company Amgen Inc. rose $2, or 4.1 percent, to $50.84. Shares of Juniper Networks Inc. , which develops networking products, gained 88 ...
Comment?
-
Amgen Diminished Shares Look to `Savior' With Osteoporosis Drug Denosumab
Amgen Inc. 's experimental osteoporosis drug may become the top remedy for the bone- thinning disorder, gaining about half of an $8 billion annual market and reviving shares.
Comment?
-
Controlling bone disease improves survival of hemodialysis patients
... of Outcomes Insights, Inc. (Newbury Park, CA), and his colleagues, Dr. Vasily Belozeroff and Dr. Karen Smirnakis of Amgen, Inc. (Thousand Oaks, CA) and Dr. Kenneth Rothman of Research Triangle Institute (Research Triangle Park, NC), set out to ...
Comment?
-
Priority security lines are coming to Delta terminal at LAX
... flight is something you can't put a value on," said Bryan Martinez, 37, of Thousand Oaks, a marketing executive for Amgen Inc. who has used the Clear system for several years at other airports. Martinez, who flies frequently on business, said that ...
Comment?
-
Carbonyl Reductase Inactivation May Contribute to Mouse Lung Tumor...
... Anschutz Medical Campus, University of Colorado Denver, Box 6511, Aurora, Colorado 80045. †Current address: Amgen, Inc., 4000 Nelson Rd., Longmont, CO 80503. *To whom correspondence should be addressed. Tel: 303-315-6167. Fax: 303-315-0274. ...
Comment?
-
Amgen's Experimental Treatment May Blunt Worst Thyroid Tumors, Study Finds
Amgen Inc. 's experimental cancer drug motesanib blunted or reversed growth of thyroid tumors in a small study of patients with the most-serious stage of the disease.
Comment?
-
Amgen's Experimental Drug Motesanib May Slow Thyroid Cancer, Study Finds
Amgen Inc. 's experimental cancer drug motesanib delayed or reversed growth of thyroid tumors in a small study of patients with advanced malignancies.
Comment?
-
... in your mutual funds. See anything familiar? Worse, even if your fund manager did stumble on a category-killer like Amgen (Nasdaq: AMGN ) or some other massive gainer, what are the chances he would actually hold on for the entire ride? More likely, ...
Comment?
-
VLST Corporation Appoints Internationally Recognized Researcher Paul...
... including as vice president, since 2004. Prior to that, Dr. Carter was director of research, antibody technologies for Amgen (Nasdaq: AMGN), Inc. following the acquisition of Immunex Corporation in 2002. Dr. Carter joined Immunex in 2000 and was the ...
Comment?
-
... faring. Here's how several key biotechnology stocks performed Wednesday: Gilead Sciences Inc., up 3 cents at $52.20. Amgen Inc., down 26 cents to $48.38. Biogen Idec Inc., down 24 cents to $59.10 Genentech Inc., down 58 cents to $77.98. Next ...
Comment?
-
Is 3SBio Too Conservative to Move Forward?
... EPO-TPO markets have been roiled by cardiovascular side effects, a problem that has negatively affected companies like Amgen (NSDQ: AMGN ). The gist of the issue is that kidney dialysis patients do just as well on lower doses of EPO, and the lower ...
Comment?
-
DxS Launches Cancer Mutation Kit For K-RAS In Australia - New...
... diagnostics." In January this year, the TheraScreen diagnostic was launched to screen patients prior to use of Amgen's EGFR inhibitor, Vectibix, given as a monotherapy for the treatment of metastatic colorectal cancer who have failed previous ...
Comment?
-
DxS Launches Cancer Mutation Kit For K-RAS In Australia - New ...
... diagnostics." In January this year, the TheraScreen diagnostic was launched to screen patients prior to use of Amgen's EGFR inhibitor, Vectibix, given as a monotherapy for the treatment of metastatic colorectal cancer who have failed previous ...
Comment?
-
Opportunities and challenges face biotech companies outside of Boston
... more funds for lab space, workforce training and economic incentives. The as-yet-unnamed group is being organized by Amgen Inc. and the Biotechnology Industry Organization (BIO), according to one of the organizers, Gary Goodrich , CEO of ...
Comment?
-
What's the Story on Amgen Shorts?
... and position themselves to make money if/when they do. Anyway, this weekend one name on the list jumped out at me: Amgen ( AMGN ). According to Barron's , the number of Amgen shares being shorted skyrocketed 114 percent from May 30th to June 13th. ...
Comment?
-
... 28% of its total holdings in any given year.) Its top holdings recently included Coventry Health Care (NYSE: CVH ) , Amgen (Nasdaq: AMGN ) , and J.C. Penney (NYSE: JCP ) . To find winning funds, take a free trial of our Motley Fool Champion Funds ...
Comment?
-
Health Winners & Losers: Myriad Genetics
... $677.7 million, vs. his $640 million estimate. Shares were up $2.26, or 3.1%, at $74.98. The prescription data suggest Amgen's AMGN Aranesp and Epogen sales are also likely to surpass consensus targets with Aranesp sales remaining relatively flat ...
Comment?
Amgen Forum
Most Popular
